Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-15
2006-08-15
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000
Reexamination Certificate
active
07091183
ABSTRACT:
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7–30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).
REFERENCES:
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495, Aug. 1994.
Marx J. Obesity gene discovery may help solve weighty problem [news]. SCIENCE, (Dec. 2, 1994) 266 (5190) 1477-8.
Woods et al., Signals that regulate food intake and energy homeostasis. Science, 280:1378-1383, May, 29, 1998.
Gelling et al. (GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept Apr. 30, 1997;69(3):151-4.
Ebert et al. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology, (Nov. 1982) 111 (5) 1601-6.
Avis, K.E. “Parenteral Preparations”, Chapter 84, in, Remington's Pharmaceutical Sciences, 18th edition (Jun. 1990), Mack Pub. Co., Easton, Pennsylvania, p. 1565.
Turco, S.J. “Intravenous Admixtures”, Chapter 85, in, Remington's Pharmaceutical Sciences, 18th edition (Jun. 1990), Mack Pub. Co., Easton, Pennsylvania, p. 1570.
Moody et al. The isolation and sequencing of human gastric inhibitory peptide (GIP). FEBS Lett. Jul. 9, 1984;172(2):142-8.
Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, James U. Bowie, et al., Science, vol. 247.
Neville Linda
Tseng Chi-Chuan
Wolfe M. Michael
Boston Medical Center Corporation
Edwards Angell Palmer & Dodge LLC
Manso Peter J.
Romeo David
LandOfFree
Specific antagonists for glucose-dependent insulinotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific antagonists for glucose-dependent insulinotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific antagonists for glucose-dependent insulinotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701956